货号:A148893
同义名:
多西环素盐酸盐半乙醇半水合物
/ WC2031; Doxycycline hydrochloride hemiethanolate hemihydrate
Doxycycline hyclate是一种口服活性、广谱抗生素和金属蛋白酶(MMP)抑制剂。它表现出抗菌和抗癌细胞增殖活性。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Doxycycline hyclate is a common broad-spectrum antibiotic. It is also an inhibitor of MMP-8 (nuclear collagenase; IC50 = 30 μM). It also has a certain inhibitory effect on MMP-1 (collagenase-1, IC50 = 300 μM). Its adequate oral absorption and extended half-life, which allows fewer daily doses. Doxycycline hyclate is considered the tetracycline of choice in patients with poor renal function due to its limited clearance by kidneys. It is active against protozoa and can be administered in combination with quinine in the management of chloroquine resistant plasmodium falciparum infection[3]. |
| Concentration | Treated Time | Description | References | |
| HeLa cells | 5 ng/ml | Induce the expression of hSSB1-WT or hSSB1-DM | Signal Transduct Target Ther. 2020 Jun 24;5(1):80. | |
| H1 cells | 1 μM | 2 or 3 days | To assess the function of SMARCB1 in steady state hESCs, qPCR and western blot results showed strong downregulation of SMARCB1 at the transcript and protein levels | Elife. 2019 Apr 29;8:e45672. |
| A375VR4 | 1 µg/mL | 5–6 days | To induce shRNA expression for studying the effects of MTH1 knockdown. | Cell Death Differ. 2020 Jul;27(7):2081-2098. |
| human fibroblasts | 100 ng/mL | 24 h | To investigate the effect of Doxycycline-induced myr-Akt expression on HCMV replication, results showed that myr-Akt expression caused a roughly 10-fold decrease in viral replication. | mBio. 2022 Aug 30;13(4):e0104222. |
| HMLE-Twist-ER cells | 1–2 μg/mL | 15 days | Induced LRIG1 expression to limit the expression of EMT markers. Results showed that LRIG1 expression blunted the expression of Fibronectin, Slug, and CD44, indicating that LRIG1 restricts the full expression of EMT markers. | Oncogene. 2016 Jun 2;35(22):2932-47. |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | H1299 xenograft model | Oral | 625 mg/kg | Daily for 4 weeks | To investigate the effect of SAT1 overexpression on tumor growth, results showed that SAT1 induction significantly suppressed xenograft tumor growth. | Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6806-E6812 |
| Nude mice | HCT116 xenograft model | Intraperitoneal injection | 5 mg/kg | Every 2 days for 10 days | Evaluate the effect of combined treatment of 2-D08 and etoposide on tumor growth | Signal Transduct Target Ther. 2020 Jun 24;5(1):80. |
| Mice | TGFα-induced pulmonary fibrosis model | Oral | 62.5 mg/kg | 6 weeks | Induced overexpression of TGFα by feeding mice with doxycycline-containing chow to establish a pulmonary fibrosis model. | EMBO Mol Med. 2020 Sep 7;12(9):e12131 |
| Mice | Cutaneous squamous cell carcinoma (SCC) model | Oral | 200mg | Continuous administration | To induce RNAi-mediated knockdown of the SOX2 gene to study its role in cutaneous squamous cell carcinoma growth. Results showed that SOX2 knockdown significantly reduced tumor growth. | Nat Commun. 2014 Jul 31;5:4511 |
| Mice | ATG5i mouse model | Dietary administration | 200 ppm | 6 weeks | To evaluate the effects of systemic Atg5 knockdown, ATG5i mice exhibited many phenotypes similar to tissue-specific knockout models, such as hepatomegaly, reduced adipose tissue, and pancreatic degeneration | Autophagy. 2018;14(7):1256-1266 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
0.97mL 0.19mL 0.10mL |
4.87mL 0.97mL 0.49mL |
9.75mL 1.95mL 0.97mL |
|
| CAS号 | 24390-14-5 |
| 分子式 | C46H58Cl2N4O18 |
| 分子量 | 1025.87 |
| SMILES Code | O=C(C1=C(O)[C@@H](N(C)C)[C@@]([C@@H](O)[C@@]2([H])C(C(C3=C(O)C=CC=C3[C@@H]2C)=O)=C4O)([H])[C@@]4(O)C1=O)N.O=C(C5=C(O)[C@@H](N(C)C)[C@@]([C@@H](O)[C@@]6([H])C(C(C7=C(O)C=CC=C7[C@@H]6C)=O)=C8O)([H])[C@@]8(O)C5=O)N.CCO.[H]Cl.[H]Cl.[H]O[H] |
| MDL No. | MFCD07357237 |
| 别名 | 多西环素盐酸盐半乙醇半水合物 ;WC2031; Doxycycline hydrochloride hemiethanolate hemihydrate; Doxycycline (hyclate) |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, room temperature |
| 溶解方案 |
DMSO: 200 mg/mL(194.96 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 120 mg/mL(116.97 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1